Abstract 786P
Background
Endometrial cancer (EC) is the most common gynecological malignancy, and treatments based on its molecular subtypes have recently been proposed. Patient-derived xenografts (PDX) are models that preserve the heterogeneity and histology of tumors, and may mimic the effects of drugs in patients. Here, we report a preclinical study of farletuzumab ecteribulin (MORAb-202, FZEC), a novel antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα), using a panel of EC-PDX models with different molecular subtypes.
Methods
We developed a panel of 36 EC-PDX models with four molecular subtypes. We investigated FRα expression based on the H-scores. The antitumor activity of FZEC was evaluated in 24 EC-PDX models, including three POLE-mutated, two MSI-H hypermutated, 11 copy number (CN)-high, and eight CN-low tumors, with various levels of FRα expression in the four treatment groups (control saline, FZEC 5 mg/kg, 12.5 mg/kg, and eribulin 3.2 mg/kg, n=6 in each group). Each drug was administered intravenously, and tumor size was measured twice a week for a 21-day observation period. The intratumoral distribution of eribulin was periodically visualized using an anti-eribulin antibody with the Opal multi-fluorescent staining system.
Results
The median H-scores of FRα expression in the 36 PDX and original tumors were 9.5 (0–184) and 74 (11-184), respectively, indicating a trend toward decreased FRA expression on the PDX. There was no relationship between FRA expression and molecular subtypes. The efficacy of FZEC was evaluated using 24 EC-PDX models. Antitumour activity was observed across all four molecular subtypes. Tumor shrinkage was associated with FRα expression in FZEC 5 mg/kg group, whereas an overall FRA-independent tumor shrinkage was observed in FZEC 12.5 mg/kg and eribulin 3.2 mg/kg groups. Intratumoral imaging analysis using tumors on day 21st showed an association between the antitumor effect and intratumoral accumulation of eribulin.
Conclusions
These results suggest that FZEC may be a promising treatment for FRα-expressing EC of all four molecular subtypes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Center, Tokyo, Japan Saitama Medical University International Medical Center, Saitama, Japan.
Funding
Eisai.
Disclosure
K. Hasegawa: Financial Interests, Personal, Invited Speaker: MSD, AstraZeneca, Takeda, Chugai, Genmab, Kaken, Eisai, Sanofi, GSK; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Institutional, Funding, contracted research: MSD, Ono, Daiichi Sankyo, Eisai, Takeda. S. Yagishita: Financial Interests, Personal, Invited Speaker: LSI Medience. T. Nishikawa: Financial Interests, Personal, Other, Speaker's Bureau: Eisai, AstraZeneca, Takeda Pharmaceutical Company, MSD, Chugai Pharmaceutical Company, Sanofi; Financial Interests, Institutional, Other, Research funding: Daiichi Sankyo; Financial Interests, Institutional, Other, Research Funding: AstraZeneca. K. Yonemori: Financial Interests, Personal, Advisory Board: Eisai, AstraZeneca, Sanofi, Genmab, Gilead, OncoXerna, Takeda, Novartis, MSD; Financial Interests, Personal, Invited Speaker: Pfizer, Eisai, AstraZeneca, Eli Lilly, Takeda, Chugai, Fuji Film Pharma, PDR Pharma, MSD, Ono, BMS, Boehringer Ingerleim, Daiichi Sankyo, Bayer, Jansen, Sanofi; Financial Interests, Institutional, Local PI: MSD, Daiichi Sankyo, AstraZeneca, Taiho, Pfizer, Novartis, Takeda, Chugai, Ono, Sanofi, Seagen, Eisai, Eli Lilly, Genmab, Boehringer Ingelheim, Kyowa Hakko Kirrin, Nihon Kayaku, Haihe. K. Furuuchi: Financial Interests, Personal, Full or part-time Employment: Eisai Inc. T. Uenaka: Financial Interests, Personal, Full or part-time Employment: Eisai Inc., Eisai Co., Ltd.; Financial Interests, Personal, Stocks/Shares: Eisai Co., Ltd. A. Hamada: Financial Interests, Funding: Eli Lilly, AstraZeneca, Boehringer Ingelheim, Eisai, Sysmex, Chordia therapeutics, Helios, Konica Minolta. All other authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11